Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on February 1, 2022, the Company granted an equity-based award pursuant to the Company's 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee. This inducement grant was approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The inducement grant consisted of non-statutory stock option to purchase 14,000 shares of the Company's common stock.

The stock options each have an exercise price of $14.43 per share, equal to the closing price of Iveric Bio's common stock on February 1, 2022. The stock option has a ten-year term and vests over four years, with 25% of the shares underlying the option vesting on February 1, 2023 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive month thereafter. The vesting of the grant is subject to the employee's continued service with the Company through the applicable vesting date. The inducement grant is subject to the terms and conditions of award agreement covering the grant and the Company's 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients' lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

ISEE-G


These press releases may also interest you

at 15:47
Today, First Bight Ventures, a Houston-based venture firm that focuses exclusively on the advancement and acceleration of early-stage Synthetic Biology companies, announced that it has added Alan McCollough to its growing panel of expert advisors....

at 15:45
IDEX CORPORATION announced today that it has scheduled the broadcast of the company's third quarter earnings conference call over the Internet on Wednesday, October 26, 2022 at 9:30 a.m. CT. Chief Executive Officer and President Eric Ashleman and...

at 15:38
Connecticut-based post-acute care provider Whispering Pines Rehabilitation and Nursing Center today announced that it has selected Medline to implement software platforms to engage frontline staff and help simplify daily tasks so they can focus on...

at 15:37
Aridis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it intends to offer its common stock in a public...

at 15:18
The Honourable Mona Fortier, President of the Treasury Board, made the following statement today regarding improvements to the Public Service Health Care Plan (PSHCP): "I am very pleased to announce that the Government has approved a new Public...

at 15:10
Summary Product: Philips Respironics sleep therapy masks with magnets in the headgear clips or straps (Amara View Full Face Mask; DreamWisp Nasal Mask; DreamWear Full Face Mask; Wisp and Wisp Youth Nasal Mask; and Therapy Mask 3100 NC/SP)Issue:...



News published on 2 february 2022 at 08:10 and distributed by: